Volume 7, Number 3—June 2001
Research
Melioidosis: An Emerging Infection in Taiwan?
Po-Ren Hsueh*, Lee-Jene Teng*, Li-Na Lee*†, Cheong-Ren Yu*, Pan-Chyr Yang*, Shen-Wu Ho*†, and Kwen-Tay Luh*
Table 1
Clinical characteristics of 15 patients in Taiwan with invasive infections caused by Burkholderia pseudomallei
| Patient no./ref | Age/ sex | Travel history | Underlying diseases/associated conditions | Clinical diagnosis | Isolate source (date) | Treatment | Out-come |
|---|---|---|---|---|---|---|---|
| 1 (13) | 46/M | Philippines | Near drowning | Cavitary pneumonia | Blood (9/82) | Cephalothin, amikacin (30 d) | Surv |
| 2 (14) | 75/F | None | Liver cirrhosis, uremia, DM | Pneumonia, peritoni-tis | Blood, ascites (8/94) | Cefazolin, gentamicin (1 d) | Died |
| 3 (14) | 70/M | None | None | Pneumonia | Blood (8/94) | Ceftazidime (30 d), amoxicillin-clavulanate (3 mo) | Surv |
| 4 (15) | 70/M | China | None | Mycotic aneurysm | Blood (11/94); aortic tissue (12/94) | Ceftazidime (35 d); amoxicillin-clavulanate (6 mo) | Surv |
| 5 (16) | 75/M | None | DM | Pneumonia | Blood (11/96) | Ceftazidime (14 d); amoxicillin-clavulanate (2 mo ) | Surv |
| 6 (17) | 51/M | Burma | DM | Pneumonia, adrenal gland abscess | Blood (7/97) | Ceftazidime (2 d);cotrimoxazole (60 d) | Surv |
| 7 (18) | 40/M | None | DM | Pneumonia, ARDS | Blood (7/97) | Moxalactam 9 d); netilmicin (9 d); erythromycin (9 d) | Died |
| 8 (PR) | 56/M | Thailand | None | Pneumonia | Blood-A (11/96) | Ceftazidime, gentamicin (1 d) | Died |
| 9 (PR) | 67/M | None | COPD | Pneumonia | Blood-B (1/97) | Ceftazidime (14 d); amoxicillin-clavulanate (2 mo) | Surv |
| 10 (PR) | 73/M | None | Prostate cancer with bone metastasis; DM; cyproterone and leuprolide acetate use | Cavitary pneumonia | Lung aspirate -C1 (7/97); sputum-C2 (7/97) | Ciprofloxacin (5 mo) | Surv |
| 11 (PR) | 76/F | None | None | Septic arthritis, subcutaneous abscess | Blood-D1; blood-D2; synovial fluid-D3; abscess fluid-D4; wound drainage -D5; all 9/98 | Ciprofloxacin (4 mo); surgical drainage | Surv |
| 12 (PR) | 58/M | None | None | Subcutaneous abscess | Abscess fluid-E1 (4/99); abscess fluid-E2 (2/2000) | Piperacillin (10 d); ciprofloxacin (14 d) | Surv |
| 13 (PR) | 66/M | None | DM | Pneumonia, septic arthritis, subcutaneous abscess | Lung aspirate -F1 (5/99); synovial fluid-F2 (5/99); abscess aspirate -F3 (1/2000) | Imipenem (10 d); ciprofloxacin (2 mo); meropenem (1 mo); amoxicillin-clavulanate (4 mo) | Surv |
| 14 (PR) | 74/M | None | COPD | Pneumonia | Blood-G (9/99) | Ceftazidime, amikacin (14 mo); ciprofloxacin (2 mo) | Surv |
| 15 (PR) | 70/M | None | COPD, TB | Pneumonia, empyema, ARDS | Blood-H1 Blood-H2 (1/2000) | Ceftazidime, amikacin (1 mo) | Died |
Abbreviations used in this table: ARDS, adult respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; d, day; DM, diabetes mellitus; mo, month; PR, present report; surv, survived.
Page created: April 26, 2012
Page updated: April 26, 2012
Page reviewed: April 26, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.